Caira Surgical is innovating radar technology to make it precise enough for use in navigating surgeons through knee-replacement procedures, where every millimeter matters for an accurate outcome, co-founders Jon Greenwald and Mort Meftah explain to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Greenwald and Meftah sit down with BI analyst Matt Henriksson for an in-depth interview about Caira, how sub-millimeter radar technology can be an improvement over traditional optical tracking for orthopedic surgery and the potential path to expand navigation and robotic capabilities within ambulatory surgical centers.

Caira Surgical is innovating radar technology to make it precise enough for use in navigating surgeons through knee-replacement procedures, where every millimeter matters for an accurate outcome, co-founders Jon Greenwald and Mort Meftah explain to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Greenwald and Meftah sit down with BI analyst Matt Henriksson for an in-depth interview about Caira, how sub-millimeter radar technology can be an improvement over traditional optical tracking for orthopedic surgery and the potential path to expand navigation and robotic capabilities within ambulatory surgical centers.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

Caira’s New Vision for Knee Surgery

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/ba6c2f83-7f5a-4ff7-ae6b-b10200edae93/transcript

“I wake up every day wanting to make health care better,” says Halle Tecco, founder of Rock Health and author of Massively Better Healthcare. Tecco joins Bloomberg Intelligence analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast to reflect on digital health’s evolution — from her early days at Apple’s App Store to building one of the sector’s first venture funds. She explains why Covid reset adoption curves, how hospitals became leading tech buyers and why aligning “margin and mission” now shapes her investment lens. Tecco also shares lessons from backing a laundry list of well-known startups, teaching at Columbia and Harvard, and why she wrote a book to empower the next wave of innovators.

&ldquo;I wake up every day wanting to make health care better,&rdquo; says Halle Tecco, founder of Rock Health and author of Massively Better Healthcare. Tecco joins Bloomberg Intelligence analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast to reflect on digital health&rsquo;s evolution &mdash; from her early days at Apple&rsquo;s App Store to building one of the sector&rsquo;s first venture funds. She explains why Covid reset adoption curves, how hospitals became leading tech buyers and why aligning &ldquo;margin and mission&rdquo; now shapes her investment lens. Tecco also shares lessons from backing a laundry list of well-known startups, teaching at Columbia and Harvard, and why she wrote a book to empower the next wave of innovators.

Halle Tecco on AI, Boom-Bust Cycles and Building Better Care

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/829d78ac-1565-4be9-8a86-b40200d208ea/transcript

“Being privately held and being a pure play spine company has given us the focus, the resourcing and the investment we need to, to really take this thing and make it hum,” Highridge’s CEO Rebecca Whitney says about the 7th largest spine company. In this Vanguards of Health Care episode, Whitney sits down with BI analyst Matt Henriksson for an in-depth interview about the path to a private company from a subsidiary under a major, publicly traded ortho company. As an independent company, she explains how it can be nimble in M&A, including the acquisition of key expandable spinal implants from Accelus and the recent PathKeeper agreement, both of which augment Highridge’s portfolio that houses its Mobi-C cervical disc replacement system and Tether motion preservation system. She also explains the importance of saying yes to new roles to build your career trajectory.

&ldquo;Being privately held and being a pure play spine company has given us the focus, the resourcing and the investment we need to, to really take this thing and make it hum,&rdquo; Highridge&rsquo;s CEO Rebecca Whitney says about the 7th largest spine company. In this Vanguards of Health Care episode, Whitney sits down with BI analyst Matt Henriksson for an in-depth interview about the path to a private company from a subsidiary under a major, publicly traded ortho company. As an independent company, she explains how it can be nimble in M&amp;A, including the acquisition of key expandable spinal implants from Accelus and the recent PathKeeper agreement, both of which augment Highridge&rsquo;s portfolio that houses its Mobi-C cervical disc replacement system and Tether motion preservation system. She also explains the importance of saying yes to new roles to build your career trajectory.

Highridge Goes Private to Expand Differentiated Offering in Spine

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/28cb618b-c07f-41c2-891c-b3fc013f4647/transcript

“We’re going to continue to drive innovation across the entire product portfolio, which also includes how we manufacture sensors,” Dexcom CEO Jake Leach tells Bloomberg Intelligence, outlining the company’s strategy to expand the use of continuous glucose monitors to more diabetic patients and beyond. In this Vanguards of Health Care podcast episode, Leach joins BI analyst Matt Henriksson for an in-depth discussion on Dexcom’s transition to the G7 15 Day sensor, aimed to reduce the frequency of changing sensors, as well as clinical data efforts to expand reimbursement to diabetic patients not on insulin and updates on the next-generation G8. He also reflects on his 22-year journey at Dexcom, rising from an engineer on a 30-person team to CEO of an 11,000-employee company.

&ldquo;We&rsquo;re going to continue to drive innovation across the entire product portfolio, which also includes how we manufacture sensors,&rdquo; Dexcom CEO Jake Leach tells Bloomberg Intelligence, outlining the company&rsquo;s strategy to expand the use of continuous glucose monitors to more diabetic patients and beyond. In this Vanguards of Health Care podcast episode, Leach joins BI analyst Matt Henriksson for an in-depth discussion on Dexcom&rsquo;s transition to the G7 15 Day sensor, aimed to reduce the frequency of changing sensors, as well as clinical data efforts to expand reimbursement to diabetic patients not on insulin and updates on the next-generation G8. He also reflects on his 22-year journey at Dexcom, rising from an engineer on a 30-person team to CEO of an 11,000-employee company.

Dexcom Aims to Expand CGM Benefits to All Diabetic Patients and Beyond

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/891c992b-786d-4127-aa5e-b3f601084d6c/transcript

Caira’s New Vision for Knee Surgery

In 1 playlist(s)

Vanguards of Health Care by Bloomberg Intelligence

Social links

Follow podcast

Recent clips